drugset / Trial / NCT03973697
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of Clostridium difficile infection (C diff).
Timeline
- Start
- 2020-01-13
- Primary completion
- 2021-08-11
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped: “Administrative reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Penn Microbiome Therapy - 001 | Unknown | — | — |
| Subject | Penn Microbiome Therapy - 002 | Unknown | — | — |
| Subject | Penn Microbiome Therapy - 003 | Unknown | — | — |